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 Abstract 
Objective: Recurrent aphthous stomatitis (RAS) is the most common and painful oral in-
flammatory lesion with an unknown etiology. This study aims to determine the therapeutic 
effects of ibuprofen, diphenhydramine and aluminum magnesium simethicone (AlMgS) 
syrup on reducing oral aphthous ulcer pain. 
Materials and Methods: Thirty-one patients with RAS participated in this double-blind 
clinical trial. Subjects were randomly divided into two groups. The control group (n=14) 
received drug mixture as drug A (diphenhydramine and AlMgS) and the case group 
(n=17) received drug B (ibuprofen, diphenhydramine and AlMgS). Drugs were topically 
applied on ulcers by the patients three times a day for 3 days. Patients were re-examined 
for the symptoms on the fourth day following their first visits using VAS (Visual Analo-
gue Scale) tool. Statistical analysis was performed using paired t-test, independent t-test 
and chi-square test. 
Results: The mean of pain reduction was 3.17±2 (P<0.001) and 3.82±1.79 (P<0.001) in 
the case and control group, respectively. The difference in pain reduction between both 
groups was not statistically significant. In addition, no significant difference was detected 
between the two groups regarding the duration of pain or burning sensation (P=0.57). 
Conclusion: The results of this study demonstrate that in comparison with diphenhydra-
mine and AlMgS syrup, the studied mixture did not effectively reduce the level of pain, 
duration and burning sensation.  
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INTRODUCTION  
Recurrent aphthous stomatitis (RAS) is the 
most painful oral lesion with a considerable 
prevalence (a mean of 20%) characterized by 
recurring ulcers confined to the oral mucosa 
with no other signs of disease [1]. 
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A mature ulcer possesses a yellow necrotic 
center and a smooth clear margin circum-
scribed by erythematous haloes. Chiefly the 
buccal mucosa and lip are infected. Kerati-
nized mucosa of the palate and gingiva are 
less often involved [2]. 
Of the etiologic point of view, aphthous sto-
matitis is a multifactorial lesion; however, the 
main etiology still remains unknown [3]. 
Trauma, [4] infectious agents, [5] hormonal 
factors, [4] genetic susceptibility, [6] hemato-
logic factors, [7] immunologic abnormalities, 
[8] stress [9] and allergy [10] are considered 
as the predisposing factors [11]. 
Treatment of RAS is symptomatic and chiefly 
empirical [12]. The most common aphthous 
ulcer treatments include applying topical 
agents such as antibiotics [13] and analgesics 
[14] to immunosuppressive agents. [11] Corti-
costeroids are routinely prescribed for the 
treatment of these lesions, while the consump-
tion of this medication is eliminated due to the 
several side effects of this drug [15, 16]. Di-
phenhydramine and aluminum magnesium 
simethicone (AlMgS) syrup have long been 
prescribed as analgesic mouthwash in order to 
decrease a great number of the symptoms of 
oral ulcers such as aphthous ulcers [16]. Ibu-
profen is a potent non-steroidal anti-
inflammatory drug (NSAID) with fair anti-
inflammatory potential prescribed in dental 
pain [17]. 
A double-blind study conducted by Collier et 
al. (1992) that had assessed 22 patients af-
fected by RAS suggested that 5-aminosalicilic 
acid (5-ASA) cream should be considered as 
an effective therapeutic approach for aphthous 
ulcers. [18] Saxen et al. (1997) studied 60 pa-
tients affected by RAS and they demonstrated 
that a single dose of 3% diclofenac in 2.5% 
hyaluronan resulted in a significant decrease 
in pain [19]. 
Therefore, we studied the therapeutic efficacy 
of ibuprofen, diphenhydramine and AlMgS 
syrup in the treatment of recurrent aphthous 
stomatitis. 
MATERIALS AND METHODS 
This double-blind randomized clinical trial 
was established in the oral medicine depart-
ment of dental faculty in Qazvin University of 
Medical Sciences, Qazvin, Iran. This clinical 
trial was registered in clinicaltrials.gov with 
NCT01293968 identifier. 
 Of the total number of patients affected by 
RAS referring to this faculty in the second half 
of 2010, individuals fulfilling the conditions of 
the trial including possessing at least one pain-
ful apththous ulcer detected in the last three 
days, age older than 10 years, lack of any sys-
temic disorder or specific syndrome (such as 
Behcet’s) in which aphthous ulcers are consi-
dered as the signs of disease  , women not ex-
periencing breastfeeding or pregnancy, no his-
tory of allergy to NSAIDs, no history of asth-
ma, peptic ulcers, hepatic and renal failures 
and hemorrhagic disorders, no consumption of 
anti-inflammatory medications in the last 24 
hours, no history of systemic corticosteroid 
consumption in the last 2 weeks were included 
in the study. After examination and approving 
the diagnosis of aphthous stomatitis, each sub-
ject signed a detailed informed consent form 
to participate in the study; meanwhile, the eth-
ical issues and principles of the study were 
approved in Iran Ethics Committee that were 
accordant with Helsinki Declaration of 1975 
as well. Thirty one  patients were randomly 
allocated to case and control groups by an epi-
demiologist. This randomization was based on 
building homogeneous unit blocks (two red 
and blue beads). If possible, a homogeneous 
block was generated and the items were ran-
domly allocated to the case and control 
groups. In lack of homogeneous blocks, each 
sample was randomly allocated to the groups. 
Afterwards, a questionnaire was filled for each 
patient based on personal data and examina-
tion results. In this questionnaire, after record-
ing personal data, such as age, gender, educa-
tion and systemic situation, the state of the 
aphthous ulcers was evaluated and the level of 
pain and irritation was assessed by VAS scale. 
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According to the pharmacist’s category, medi-
cation A (100 ml diphenhydramine 25 mg and 
100 ml AlMgS 550 mg) and medication B (5 
ml ibuprofen 100mg, 10 ml diphenhydramine 
25 mg and 10 ml AlMgS 550 mg) were ran-
domly prescribed to the patients while the in-
vestigators where blinded to these agents. 
Meanwhile, carboxy methyl cellulose was re-
cruited as the vehicle in the mixture and the 
medications A and B were randomly num-
bered as well. All patients were instructed to 
apply the gel on the site of the ulcer 30-60 mi-
nutes before meals, three times daily. On the 
fourth day, while the medication was applied 
for 3 days, the patients were clinically as-
sessed and the questionnaires were completed. 
Data analysis was performed by paired t-test, 
independent t- test and chi-square test. In this 
study P<0.05 was considered as statistically 
significant. On the other hand, out of the total 
number of 37 patients fulfilling the conditions 
of the trial, six patients (four cases and two 
controls) were excluded due to non-
compliance. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
RESULTS 
Thirty-one patients were enrolled in this study. 
The demographic data and clinical characteris-
tics are illustrated in Table 1.   
To assess intra group reduction in pain and 
irritation after treatment (VAS1 – VAS2), 
paired t-test was administered and the results 
suggested significant pain alleviation in both 
groups (details illustrated in Table 2). 
To compare VAS alternations before and after 
treatment between the two groups, indepen-
dent t-test was administered and the results 
demonstrated no statistically significant dif-
ference between the level of pain and irritation 
reduction (P= 0.358). In order to compare the 
duration of pain and irritation reduction be-
tween the groups, the history of pain duration 
and irritation of the previous ulcers were taken 
into consideration on the day of examination. 
After the intervention, duration of pain and 
irritation reduction was 0.35±3.3 and 0.29±2.7 
days in the case and control groups, respec-
tively while the difference was not statistically 
significant (P=0.57).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1. Baseline Demographic and Clinical Characteristics of the Two Groups 
Index Case (n=14) Control (n=17) P-Value 
Age 33.71±9.7 30.43±10.5 0.374 
Gender (%) 
Female: 11 (64.7%) 
Male: 6 (35.3%) 
Female: 7(50%) 
Male: 7(50%) 
0.409 
VAS1 6.65±2 5.71±2.2 0.23 
Pain Duration (day) 6.35±3.4 5.71±2.6 0.564 
 
Table 2. Mean of Pain Reduction in Case and Control Groups Before and After Treatment 
Index Case (n=17) Control (n=14) 
VAS 
Before After Before After 
6.65±2 3.47±2.7* 5.71±2.2 1.89±1.6* 
*= P<0.001 
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The power of the study was calculated as 
72.19% in comparing the means of pain and 
irritation reduction in the case and control 
groups.  
 
DISCUSSION 
In this study, ibuprofen, diphenhydramine and 
AlMgS syrup were effective in alleviating the 
pain and irritation in aphthous ulcers and VAS 
was significantly decreased by the fourth day 
in the case group. While comparing the thera-
peutic efficacy of this syrup with diphenhy-
dramine and AlMgS, no considerable change 
was detected in the decrease of irritation, dura-
tion and level of the pain in aphthous ulcers; 
consecutively, this result is inconsistent with 
the results of the study conducted by Collier et 
al. on 5-ASA medication [18] and the study 
carried out by Saxen et al. on the mixture of 
diclofenac in hyaluronan [19]. It is assumed 
that lack of a mixture as placebo in this as-
sessment accounts for the inconsistency with 
Collier’s study [18]. In fact, our suggested 
mixture was compared with the most routine 
syrup and the first choice in the treatment of 
patients affected by aphthous oral ulcers. 
There might be the possibility to detect signif-
icant statistical differences if the study was 
based on comparison of drug and placebo.In 
the study performed by Saxen et al., [19] the 
efficacy of diclofenac in hyaluronan was as-
sessed and the dosage form administered in 
their study was gel, similar to our study, al-
though their method was different. In their 
study unlike our study, the single dose effects 
were assessed and VAS was evaluated 10 mi-
nutes after applying gel. In another study con-
ducted on children affected by Behcet’s dis-
ease, prior to the diagnosis of Behcet’s dis-
ease, NSAID was prescribed and consecutive-
ly some joint symptoms improved while no 
improvement was observed in the other symp-
toms [20]. The other issue that must be taken 
into consideration is that ibuprofen was admi-
nistered in aphthous ulcers therapy for the first 
time in our study and to our knowledge, no 
other study has been conducted on the pre-
scription of this medication, either as a single 
drug or in combination with other drugs in the 
treatment of aphthous. Furthermore, the dose 
prescribed through our study was 20 g/L, 
while we assume that by increasing the dose 
of ibuprofen and applying different concentra-
tions, the results might change. 
 
CONCLUSION 
Generally, it is concluded that NSAIDs are not 
truly potent medications for reducing pain and 
irritation in aphthous ulcers and studies on a 
larger number of subjects by applying differ-
ent concentrations may be needed to assess the 
efficacy of these drugs in improving the signs 
of these lesions. According to the results ob-
tained from this study, it is demonstrated that 
compared to diphenhydramine and AlMgS, 
ibuprofen, diphenhydramine and AlMgS syrup 
is not a potent medication in reducing the pain 
level, duration and irritation of recurrent aph-
thous stomatitis ulcers. Therefore, prescribing 
this medication to the patients affected by 
RAS is not suggested until there are more stu-
dies conducted on this issue. 
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